Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430638 · ClinicalTrials.gov registry record · Phase 4
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
A Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 278
- Enrollment target
- 20
- Study locations
NCT00430638: Completed Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.
NCT00430638 is a Phase 4 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 278 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430638, a Phase 4 study of Hypertension, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 278 participants
- Enrollment target
- 20
- Study locations
Study Summary
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
Primary Outcome
The change from baseline in mean systolic blood pressure (SBP) after 12 weeks of randomized treatment was compared between the olmesartan based treatment group and the placebo treatment group.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG olmesartan medoxomil + hydrochlorothiazide, if necessary
Study Locations (20)
Florida
- - Coral Gables
- - Deerfield Beach
- - DeLand
- - Fort Lauderdale
- - Hialeah
- - Hollywood
- - Pembroke Pines
Alabama
- - Birmingham
- - Mobile
- - Muscle Shoals
California
- - Carmichael
- - Spring Valley
Arkansas
- - Searcy
Illinois
- - Chicago
New Jersey
- - Elizabeth
North Carolina
- - Winston-Salem
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
What the finished NCT00430638 record still lists
NCT00430638 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00430638 names 20 study sites across 11 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00430638 about?
NCT00430638 is a clinical study titled "A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension". This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
What is the current status of trial NCT00430638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 278 participants. The study started on 2006-12. Estimated completion is 2007-10.
What conditions does trial NCT00430638 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00430638?
The interventions under investigation include: Placebo (DRUG), olmesartan medoxomil + hydrochlorothiazide, if necessary (DRUG).
Who is sponsoring clinical trial NCT00430638?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00430638 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00430638's enrollment target sits among peer trials
278 186th of 470 higher than 284 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05489237 · 278 participants · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia